Jim Cramer Wasn’t Selling Eli Lilly (LLY)
Key takeaways
- Jim Cramer Wasn’t Selling Eli Lilly (LLY) Ramish Cheema Sat, June 13, 2026 at 9:06 PM GMT+7 1 min read LLY SPCX We recently published
- Jim Cramer Didn’t Hold Back On Space X’s IPO & Discussed These 12 Stocks.
- Healthcare and pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is one of Jim Cramer’s favorite stocks.
Jim Cramer Wasn’t Selling Eli Lilly (LLY) Ramish Cheema Sat, June 13, 2026 at 9:06 PM GMT+7 1 min read LLY SPCX We recently published
Jim Cramer Didn’t Hold Back On Space X’s IPO & Discussed These 12 Stocks. Eli Lilly and Company (NYSE:LLY) is one of the stocks discussed by Jim Cramer.
Healthcare and pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is one of Jim Cramer’s favorite stocks. Throughout 2025, the CNBC TV regularly praised the firm for a multitude of factors. These included its lead in the weight loss drug race, a diverse product portfolio, and efforts to establish a robust manufacturing presence in America. Eli Lilly and Company (NYSE:LLY)’s shares are up by 40% over the past year and by 5% year-to-date. Jefferies discussed the firm on June 9th as it raised the share price target to $1,350 from $1,330 and kept a Buy rating on the stock. The coverage was based on Eli Lilly and Company (NYSE:LLY)’s retatrutide drug, which the bank noted would be difficult to compete against in the obesity market. Cramer discussed the firm in a brief tweet on June 8th: